Marker Therapeutics, Inc.

A major leap forward in cell therapy

Marker Therapeutics Reports Update from TACTOPS Trial with MultiTAA-Specific T Cell Therapy in Pancreatic Cancer at ASCO20

The Company

We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Marker Therapeutics, Inc. today announced updated clinical results from an ongoing investigator-sponsored Phase 1 trial led by the Baylor College of Medicine, evaluating the Company’s MultiTAA-specific T cell therapy in patients with advanced or metastatic pancreatic adenocarcinoma. Data from a cohort of patients receiving MultiTAA-specific T cell therapy in combination with standard-of-care chemotherapy in the first-line setting (Arm A), were reviewed today by lead investigator, Brandon G. Smaglo, M.D., FACP, as part of a poster session during the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting. ASCO is being held from Friday, May 29 through Sunday, May 31, 2020.

Read more

Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at ASCO 2020 Annual Meeting

Marker Therapeutics, Inc. today announced that updated clinical data from an investigator-sponsored Phase 1/2 trial led by Baylor College of Medicine were selected for presentation during a poster session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

Read more